Search

555 Result(s)
Sort by

Transforming Science Day

Transforming Science Day

How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Ingelheim

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
global-top-employer

global-top-employer

For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
About Office Hours

About Office Hours

Boehringer Ingelheim Office Hours mentors early-stage life-science companies providing access to expertise, an industry perspective and feedback.
Focus on Alliance Management

Focus on Alliance Management

Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.